الفهرس 
List of contentsOnly 14 pages are availabe for public view
 |  | from | 194 |  |  |
| | | from | 194 | | |
Abstract
the results of study provide a new clue in the understanding of the complexity of cirrhotic cardiomyopathy confirming the presence of diastolic dysfunction and suggesting hypertrophy as the structural myocardial abnormality producing diastolic dysfunction in patients with post viral compensated cirrhosis. Diastolic Dysfunction is prevalent among HCV infected patients and its prevalence increase with advanced fibrosis stages. These findings also introduced a new consideration on the potential role of drugs such as beta blockers, angiotensin II receptor antagonists and aldosterone antagonists: their therapeutic application in earlier stages of the cirrhotic disease might prove useful in the clinical management of cirrhotic cardiomyopathy before decompensation of disease develops. This study needs further investigations devoted to better clarify the effects of HCV on extrahepatic tissues and in particular the myocardial tissue.